Source:http://linkedlifedata.com/resource/pubmed/id/11368367
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2001-5-22
|
pubmed:abstractText |
From 1987 to 1999 35 patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation (SCT) at the University Hospitals of Vienna and Graz. Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). All patients surviving 28 days engrafted. Twenty-eight of them (93%) attained clinical remission. At the last follow-up 14 patients were alive and disease-free at a median of 5.0 (range, 2.3-12.9) years after allogeneic SCT. The actuarial overall survival is 35%. Five patients relapsed 1.8 to 27.6 months after transplant, the probability of relapse is 23%. Of the 21 deaths following SCT, seven were due to relapse/refractory disease and 14 due to transplant-related causes. The probability of treatment-related mortality is 48%. After SCT, minimal residual disease (MRD) was monitored by polymerase chain reaction (PCR) in seven patients with a BCL-2/IgH translocation and in 13 with a clonal immunoglobulin heavy chain (IgH) rearrangement. All 20 patients attained clinical remission rapidly and converted to PCR negativity. In the follow-up nine of these patients are in long-term clinical and molecular remission, six PCR-negative patients died of transplant-related causes and five patients relapsed. In summary, allogeneic stem cell transplantation has a curative potential for patients with refractory and recurrent non-Hodgkin's lymphoma. In our series long-term disease-free survival was associated with molecular disease eradication after SCT. Treatment-related mortality rate was high, thus earlier referral of selected patients to allogeneic SCT should be considered.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0887-6924
|
pubmed:author |
pubmed-author:BruggerSS,
pubmed-author:DieckmannKK,
pubmed-author:FischerGG,
pubmed-author:GreinixH THT,
pubmed-author:HinterbergerWW,
pubmed-author:HoeckerPP,
pubmed-author:JaegerUU,
pubmed-author:KalinJJ,
pubmed-author:LechnerKK,
pubmed-author:LinkeschWW,
pubmed-author:MannhalterCC,
pubmed-author:MitterbauerGG,
pubmed-author:MitterbauerMM,
pubmed-author:NeumeisterPP,
pubmed-author:SimonitschII
|
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
635-41
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11368367-Adult,
pubmed-meshheading:11368367-Female,
pubmed-meshheading:11368367-Gene Rearrangement,
pubmed-meshheading:11368367-Genes, Immunoglobulin,
pubmed-meshheading:11368367-Genes, bcl-2,
pubmed-meshheading:11368367-Graft vs Host Disease,
pubmed-meshheading:11368367-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11368367-Humans,
pubmed-meshheading:11368367-Immunoglobulin Heavy Chains,
pubmed-meshheading:11368367-Lymphoma, Non-Hodgkin,
pubmed-meshheading:11368367-Male,
pubmed-meshheading:11368367-Middle Aged,
pubmed-meshheading:11368367-Polymerase Chain Reaction,
pubmed-meshheading:11368367-Prognosis,
pubmed-meshheading:11368367-Transplantation, Homologous
|
pubmed:year |
2001
|
pubmed:articleTitle |
Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma.
|
pubmed:affiliation |
Department of Medicine I, University Hospital of Vienna, Austria.
|
pubmed:publicationType |
Journal Article
|